Cemiplimab as Maintenance Treatment for Advanced Adrenocortical Cancer

Launched by AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA · Jul 24, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called cemiplimab as a “maintenance” therapy for people with advanced adrenocortical carcinoma (ACC), a rare cancer of the adrenal glands. The goal is to see if cemiplimab can help keep the cancer from getting worse or coming back after patients have already received initial chemotherapy and surgery, and their disease has either improved or stayed stable.

Adults over 18 with confirmed ACC who have completed first-line chemotherapy (called EDP-M) and surgery if needed, and whose cancer has not progressed, may be eligible to join. Participants should be in good overall health with well-functioning organs and able to visit the clinic regularly. Women who could become pregnant and men must agree to use effective birth control during and for some time after the study. If accepted, participants will receive cemiplimab and be monitored closely to see if it helps control their cancer and to check for any side effects. This study is not yet recruiting and will take place in Italy. It offers a chance to try a new immunotherapy that may help patients live longer without the cancer worsening.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Male and females \>18 years of age;
• • 2. Patients with histologically confirmed ACC;
• • 3. Previous induction therapy with EDP-M followed by cytoreductive surgery if indicated;
• • 4. No disease progression after first line 4-6 EDP-M cycles;
• • 5. An ECOG PS of 0, 1;
• 6. Adequate organ and bone marrow function documented by:
• • 1. Hemoglobin \>9.0 g/dL
• • 2. ANC \>1.5 x 109/L
• • 3. Platelet count \>75 x 109/L
• • 4. Serum creatinine \<1.5 ULN or estimated CrCl \>30 mL/min
• 5. Adequate hepatic function:
• • Total bilirubin \<1.5 x ULN;
• • AST and ALT both \<3 x ULN;
• • ALP \<2.5 x ULN; Note: For patients with Gilbert's syndrome, total bilirubin ≤3x ULN. Gilbert's syndrome must be documented appropriately as past medical history.
• • 7. Women of child-bearing potential (physiologically capable of becoming pregnant) that must agree to follow instructions for methods of contraception (including at least one highly effective contraception method, see study protocol) for the duration of treatment with study drug, and after discontinuation of treatment as long as mitotane plasma levels are detectable and, in any case, at least for 6 months post treatment completion; must have a negative serum or urine pregnancy test within 24 hours prior to the start of study drug;
• • 8. Women must not be breastfeeding;
• • 9. Males that must agree to follow instructions for methods of contraception (see study protocol) for the duration of treatment with study drug, and then for a total of 6 months post treatment completion. In addition, male patients must not donate sperm for the time period specified above;
• • 10. Willing and able to comply with clinic visits and study-related procedures;
• • 11. Willing and able to provide informed consent signed by study patient or legally acceptable representative;
• • 12. Able to understand and complete study-related questionnaires.
• Exclusion Criteria:
• • 1. History of recent or active prior malignancy, except for cured non-melanoma skin cancer, cured in situ cervical carcinoma, breast ductal carcinoma in situ, or other treated malignancies where there has been no evidence of disease for at least 5 years;
• • 2. Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor;
• • 3. Administration of a live vaccine within 30 days of the first dose of study treatment;
• • 4. Active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs);
• • 5. Diagnosis of immunodeficiency or systemic steroid therapy (i.e., dosing exceeding 10 mg of prednisone or equivalent). In case of mitotane treatment, a maximum steroid supplementation of 75 mg of cortone acetate (or equivalent hydrocortisone dose) will be accepted;
• • 6. Uncontrolled HIV, Hepatitis B or Hepatitis C (see protocol for details);
• • 7. History of (non-infectious) pneumonitis that required steroids or current pneumonitis;
• • 8. Active infection requiring systemic therapy;
• • 9. Significant cardiovascular disease, such as: history of myocardial infarction, acute coronary syndrome or coronary angioplasty / stenting / bypass grafting within the last 6 months OR CHF NYHA Class II-IV or history of CHF NYHA Class III or IV;
• • 10. Pregnancy or breastfeeding;
• • 11. Continued sexual activity in women of childbearing potential (physiologically capable of becoming pregnant) or sexually active men who are unwilling to practice highly effective contraception (including at least one highly effective contraception method, see study protocol) prior to the initial dose/start of the first treatment, during the study, and for at least 6 months after the last dose;
• • 12. History of active tuberculosis (TB, Bacillus Tuberculosis);
• • 13. Untreated brain metastasis that may be considered active.
• • 14. Known hypersensitivity or allergy to any of the excipients in the cemiplimab drug product.
• • 15. Patients with a history of solid organ transplant (exception: corneal transplant)
• • 16. Prior allogeneic stem cell transplantation, or autologous stem cell transplantation.
• • 17. ECOG PS ≥ 2